The role of anesthetics in streamlining efficiency and elevating patient care.

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Panelists discuss how they present the modest efficacy of geographic atrophy (GA) therapies to patients by framing treatment as maintenance therapy that slows progression rather than providing ...

Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the ...

REGENXBIO initiates a pivotal trial for surabgene lomparvovec, aiming to transform diabetic retinopathy treatment and improve patient outcomes.

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

assistant professor at Emory Eye CenterArticles ASRS 2025: Outcomes in patients with noninfectious uveitis requiring secondary lens implantation Sruthi Arepalli, MD; Martin David Harp; Sydney M Crago ...

Sruthi Arepalli, MD, an assistant professor at Emory Eye Center in Atlanta, Georgia, presented a comprehensive study on secondary lens implants in patients with uveitis at the 2025 ASRS meeting.

4D Molecular Therapeutics showcases promising SPECTRA trial results for 4D-150, highlighting its potential to revolutionize diabetic macular edema treatment.

Panelists discuss how their management approach for geographic atrophy (GA) has evolved from a “come back in a year” mentality to actively offering treatment discussions within 2 to 3 months, with ...

EP: 4. Choosing Between the Currently Available GA Therapies Therapy selection between the 2 FDA-approved geographic atrophy treatments presents a complex clinical decision without clear superiority ...